Novartis Completes Divestiture of Influenza Vaccines Business to CSL Limited for $275M

By: via Benzinga
CSL Limited acquired influenza vaccines business of Novartis (NYSE: NVS), including influenza vaccines development pipeline Basel, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.